Table 4.
MSI phenotype and pathological parameters.
| Pathological Parameters | No. of Patients | MSI phenotype | p | |
|---|---|---|---|---|
| MSS | MSI-L | |||
| Age at diagnosis | 0.406 | |||
| ≤49 | 97 | 92 | 6 | |
| >49 | 98 | 89 | 9 | |
| Histological grade | 0.546 | |||
| I | 9 | 8 | 1 | |
| II | 51 | 49 | 2 | |
| III | 135 | 124 | 11 | |
| Tumor size | 0.156 | |||
| pT1 | 81 | 78 | 3 | |
| pT2 | 106 | 95 | 11 | |
| pT3 | 8 | 8 | 0 | |
| Nodal status | 0.295 | |||
| negative | 110 | 101 | 9 | |
| 1–3 nodes | 45 | 43 | 2 | |
| 4–9 nodes | 19 | 19 | 0 | |
| ≥10 nodes | 21 | 18 | 3 | |
| TNM Stage | 0.516 | |||
| I | 52 | 50 | 2 | |
| II | 101 | 92 | 9 | |
| III | 42 | 39 | 3 | |
| Basal-like | 1.000 | |||
| Negative | 43 | 40 | 3 | |
| Positive | 152 | 141 | 11 | |
| Ki67 index* | 0.473 | |||
| ≤14 | 32 | 31 | 1 | |
| >14 | 163 | 150 | 13 | |
| TILs | 0.753 | |||
| High | 49 | 45 | 4 | |
| Low | 146 | 136 | 10 | |
| Surgery | 1.000 | |||
| Breast-conserving | 20 | 19 | 1 | |
| Radical mastectomy | 175 | 162 | 13 | |
| Chemotherapy | 1.000 | |||
| Negative | 30 | 28 | 2 | |
| Positive | 157 | 146 | 11 | |
| Radiotherapy | 1.000 | |||
| Negative | 149 | 137 | 12 | |
| Positive | 34 | 32 | 2 | |
| P53 | 1.000 | |||
| Negative | 101 | 94 | 7 | |
| Positive | 93 | 86 | 7 | |
| PD-1 | 0.129 | |||
| Negative | 59 | 52 | 7 | |
| Positive | 136 | 129 | 7 | |
| PD-L1 | 0.604 | |||
| Negative | 182 | 168 | 14 | |
| Positive | 13 | 13 | 0 | |
MSI, microsatellite instability; MSS, microsatellite stable; MSI-L, low-frequency microsatellite instability; TNM, Primary Tumor/Regional Lymph Nodes/Distant Metastasis; TILs, tumor infiltrating lymphocytes; *Ki-67 index threshold of 14% was chosen according to the St. Gallen Consensus 2013.